Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -22.81% is 3134% below its 5-year average of -0.71%, around the middle of its 5-year range (-53.67%–14.02%).
24.21% above its 12-month average of -30.10%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -20.74%.
EBITDA MARGIN
-22.81%
EBITDA MARGIN AVG TTM
-30.10%
EBITDA MARGIN AVG 3Y
-8.90%
EBITDA MARGIN AVG 5Y
-0.71%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+24.21%
CURRENT VS 3Y AVG
-156.42%
CURRENT VS 5Y AVG
-3134.24%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$36.23M
EBITDA Margin
-136.01%
TTM Avg
-1016.71%
3Y Avg
-1237.80%
5Y Avg
-1237.80%
Market Cap
$35.42M
EBITDA Margin
-127.12%
TTM Avg
-129.61%
3Y Avg
-125.08%
5Y Avg
-93.97%
Market Cap
$36.63M
EBITDA Margin
-22.75%
TTM Avg
-133.81%
3Y Avg
-3828.74%
5Y Avg
-3288.72%
Market Cap
$34.58M
EBITDA Margin
-7905.63%
TTM Avg
-7905.63%
3Y Avg
-7905.63%
5Y Avg
-7905.63%
Market Cap
$34.56M
EBITDA Margin
-6.58%
TTM Avg
-1.77%
3Y Avg
-0.14%
5Y Avg
1.64%
Market Cap
$36.99M
EBITDA Margin
-1929.22%
TTM Avg
-1308.49%
3Y Avg
-1783.80%
5Y Avg
-1343.37%
Market Cap
$33.93M
EBITDA Margin
-3982.39%
TTM Avg
-3087.93%
3Y Avg
-1849.71%
5Y Avg
-2051.20%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DocGo Inc. (DCGO) | $35.76M | -22.81% | -30.10% | -8.90% | -0.71% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.62M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.23M | -136.01% | -1016.71% | -1237.80% | -1237.80% |
| Elutia Inc (ELUT)vs › | $35.42M | -127.12% | -129.61% | -125.08% | -93.97% |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.63M | -22.75% | -133.81% | -3828.74% | -3288.72% |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.58M | -7905.63% | -7905.63% | -7905.63% | -7905.63% |
| Accuray Incorporated (ARAY)vs › | $34.56M | -6.58% | -1.77% | -0.14% | 1.64% |
| Edesa Biotech, Inc. (EDSA)vs › | $36.99M | -1929.22% | -1308.49% | -1783.80% | -1343.37% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.93M | -3982.39% | -3087.93% | -1849.71% | -2051.20% |
| Incannex Healthcare Limited (IXHL)vs › | $38.35M | -27375.58% | -138216.12% | -92142.37% | -55460.65% |
Gross Margin
30.1%
EBITDA Margin
-22.8%
Operating Margin
-27.7%
Net Margin
-65.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -20.74% |
| 2026-03-31 | -21.26% |
| 2025-12-31 | -38.02% |
| 2025-09-30 | -53.67% |
| 2025-06-30 | -16.79% |
| 2025-03-31 | -10.66% |
| 2024-12-31 | -3.43% |
| 2024-09-30 | 10.32% |
| 2024-06-30 | 8.70% |
| 2024-03-31 | 10.44% |
| 2023-12-31 | 8.18% |
| 2023-09-30 | 6.99% |
| 2023-06-30 | 4.31% |
| 2023-03-31 | -2.88% |
| 2022-12-31 | 3.12% |
| 2022-09-30 | 6.92% |
| 2022-06-30 | 8.67% |
| 2022-03-31 | 10.43% |
| 2021-12-31 | 14.02% |
| 2021-09-30 | 4.12% |
| 2021-06-30 | 3.47% |
| 2021-03-31 | -0.56% |
| 2020-12-31 | -9.59% |
| 2020-09-30 | -4.42% |
| 2020-06-30 | -1.61% |
| 2020-03-31 | -35.06% |
